Ensysce Biosciences : Corporate Overview -March 28, 2024 at 09:28 am EDT

Investor Presentation | March 2024


Disclaimer


Ensysce's PF614 and nafamostat are currently in clinical trial and pre-clinical studies,...

Related Keywords

,Exchange Commission On ,Investor Presentation ,Risk Factors ,Annual Report ,Exchange Commission ,Private Securities Litigation Reform Act ,Next Generation ,Extended Release ,Markets ,